Journal
LANCET INFECTIOUS DISEASES
Volume 21, Issue 10, Pages 1333-1333Publisher
ELSEVIER SCI LTD
DOI: 10.1056/NEJMoa2026330
Keywords
-
Categories
Funding
- U.K. Joint Global Health Trials (Department of Health and Social Care) [MR/P006876/1]
- U.K. Joint Global Health Trials (Department for International Development) [MR/P006876/1]
- U.K. Joint Global Health Trials (Global Challenges Research Fund) [MR/P006876/1]
- U.K. Joint Global Health Trials (Medical Research Council) [MR/P006876/1]
- U.K. Joint Global Health Trials (Wellcome Trust) [MR/P006876/1]
- PATH Malaria Vaccine Initiative [18269]
- U.K. Medical Research Council (MRC) [MR/R010161/1]
- U.K. Foreign, Commonwealth, and Development Office
- EDCTP2 program - European Union
Ask authors/readers for more resources
This study found that seasonal vaccination with RTS,S/AS01(E) was as effective as chemoprevention in preventing uncomplicated malaria, but combining the two interventions significantly reduced the incidence of uncomplicated malaria, severe malaria, and death from malaria compared to using either intervention alone.
Background Malaria control remains a challenge in many parts of the Sahel and sub-Sahel regions of Africa. Methods We conducted an individually randomized, controlled trial to assess whether seasonal vaccination with RTS,S/AS01(E) was noninferior to chemoprevention in preventing uncomplicated malaria and whether the two interventions combined were superior to either one alone in preventing uncomplicated malaria and severe malaria-related outcomes. Results We randomly assigned 6861 children 5 to 17 months of age to receive sulfadoxine-pyrimethamine and amodiaquine (2287 children [chemoprevention-alone group]), RTS,S/AS01(E) (2288 children [vaccine-alone group]), or chemoprevention and RTS,S/AS01(E) (2286 children [combination group]). Of these, 1965, 1988, and 1967 children in the three groups, respectively, received the first dose of the assigned intervention and were followed for 3 years. Febrile seizure developed in 5 children the day after receipt of the vaccine, but the children recovered and had no sequelae. There were 305 events of uncomplicated clinical malaria per 1000 person-years at risk in the chemoprevention-alone group, 278 events per 1000 person-years in the vaccine-alone group, and 113 events per 1000 person-years in the combination group. The hazard ratio for the protective efficacy of RTS,S/AS01(E) as compared with chemoprevention was 0.92 (95% confidence interval [CI], 0.84 to 1.01), which excluded the prespecified noninferiority margin of 1.20. The protective efficacy of the combination as compared with chemoprevention alone was 62.8% (95% CI, 58.4 to 66.8) against clinical malaria, 70.5% (95% CI, 41.9 to 85.0) against hospital admission with severe malaria according to the World Health Organization definition, and 72.9% (95% CI, 2.9 to 92.4) against death from malaria. The protective efficacy of the combination as compared with the vaccine alone against these outcomes was 59.6% (95% CI, 54.7 to 64.0), 70.6% (95% CI, 42.3 to 85.0), and 75.3% (95% CI, 12.5 to 93.0), respectively. Conclusions Administration of RTS,S/AS01(E) was noninferior to chemoprevention in preventing uncomplicated malaria. The combination of these interventions resulted in a substantially lower incidence of uncomplicated malaria, severe malaria, and death from malaria than either intervention alone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available